Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Florczyk, M. Kurzyna, A. Fijalkowska, A. Kacprzak, M. Wieteska, C. Czajka, J. Kober, J. Zylkowska, A. Torbicki (Warsaw, Poland). Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension. Eur Respir J 2007; 30: Suppl. 51, 1808

Member's Comments

No comment yet.

Related content which might interest you: Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 858-863 Year: 2005 Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004 Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy Source: Eur Respir Rev 2009; 18: 253-259 Year: 2009 Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006 Oct 01;28(4):691-694 Year: 2006 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Sustained efficacy with the selective endothelin-A receptor antagonist, sitaxsentan, after two years of therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 204s Year: 2005 Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Source: Eur Respir J 2004; 24: 353-359 Year: 2004 Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension}, Source: Eur Respir J 2012; 40: 874-880 Year: 2012 The new clinical trials on pharmacological treatment in pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 1037-1049 Year: 2002 Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 Survival with first-line bosentan in patients with primary pulmonary hypertension Source: Eur Respir J 2005; 25: 244-249 Year: 2005 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 The use of combination therapy in pulmonary arterial hypertension: new developments Source: Eur Respir Rev 2009; 18: 148-153 Year: 2009 Bosentan therapy for portopulmonary hypertension Source: Eur Respir J 2005; 25: 502-508 Year: 2005 Endothelin: setting the scene in PAH Source: Eur Respir Rev 2008; 17: 3-7 Year: 2007 Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids Source: Eur Respir J 2003; 22: 330-334 Year: 2003 Endothelin receptor antagonists in pulmonary arterial hypertension Source: Eur Respir J 2008; 31: 407-415 Year: 2008 NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Looking to the future: a new decade of pulmonary arterial hypertension therapy Source: Eur Respir Rev 2011; 20: 262-269 Year: 2011